4.3 Article

Analysis of Acupoints Combination for Cancer-Related Anorexia Based on Association Rule Mining

出版社

HINDAWI LTD
DOI: 10.1155/2022/4251458

关键词

-

资金

  1. Guangzhou TCM and Integrated Traditional Chinese and Western Medicine Science and Technology Project
  2. [20222A011007]

向作者/读者索取更多资源

This study investigated the rules of acupoint selection and effective combinations for treating cancer-related anorexia (CA). Through data mining, the study identified commonly used acupoint combinations for CA treatment. The results showed that acupoints such as Zusanli (ST36), Sanyinjiao (SP6), Guanyuan (RN4), Zhongwan (RN12), Neiguan (PC6), Shenmen (HT7), and Baihui (DU20) were frequently used in acupuncture prescriptions for CA.
We investigated the acupoint selection regulations and workable core acupoint combinations in cancer-related anorexia (CA) treatment. The Apriori algorithm, complemented by the FP-growth algorithm, was used to mine association rules based on retrieved randomized control trials (RCTs) and clinical control trials (CCTs). We searched the following databases for acupuncture treatment regimens for CA: PubMed, Embase, Cochrane Central, Web of Science, WanFang Data, VIP, China Journal Full-Text Database (CNKI), and SinoMed (CBM). We extracted acupoints prescriptions from the 27 enrolled RCTs and CCTs for analysis. There have been 38 acupoints refined from 27 prescriptions. The pinnacle three regularly chosen acupoints were Zusanli (ST36), Zhongwan (RN12), and Sanyinjiao (SP6). We investigated 10 association rules, and the consequences confirmed that {RN4} >= {RN12}, {PC6} >= {ST36}, {RN12, SP6} >= {RN4}, {HT7} >= {RN12}, and {DU20} >= {RN12} had been the most frequent associated rules in the adoption literature. Zusanli (ST36), Sanyinjiao (SP6), Guanyuan (RN4), Zhongwan (RN12), Neiguan (PC6), Shenmen (HT7), and Baihui (DU20) would be regarded as acupuncture prescriptions in the treatment of CA.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据